Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969 hospitalized adults with COVID-19 pneumonia in the United States, Japan, Mexico, Singapore and South Korea, the National Institutes of Health reported yesterday. In addition, interferon beta-1a was associated with more adverse events and worse outcomes in patients who required high-flow oxygen. Previous studies have found that many hospitalized patients with severe COVID-19 produce less interferon. Subcutaneous interferon beta-1a is a multiple sclerosis medication. 

Related News Articles

News
President Biden today called the new Omicron variant of the COVID-19 virus “a cause for concern, not a cause for panic,” urging all eligible Americans to get…
News
The U.S. District Court for the Eastern District of Missouri today granted a preliminary injunction preventing the Centers for Medicare & Medicaid Services…
Headline
A two-dose series of the Pfizer-BioNTech COVID-19 vaccine was 100% effective against COVID-19 in 12-15 year olds more than four months after the second dose in…
Headline
The Department of Health and Human Services today began distributing $7.5 billion of the $8.5 billion in American Rescue Plan Act payments designated for…
Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., Friday expanded eligibility for COVID-19 booster shots to include all adults…
Headline
The Health Resources and Services Administration in September gave health care providers who received more than $10,000 in Provider Relief Funds between April…